Literature DB >> 3825495

A Swedish county with unexpectedly high utilization of anti-parkinsonian drugs.

S M Aquilonius, P Hartvig.   

Abstract

This report is based on the use of L-dopa-containing drugs within 24 Swedish counties in the period 1977-1984. The mean utilization of these drugs in Sweden in 1984 was 1.46 defined daily doses (DDD)/day X 10(3) inhabitants (inh). As Parkinson's disease is virtually the only condition for which these drugs are prescribed, it seems highly probable that the determining factor for their use today is the prevalence of the disease. The exceptionally high utilization (2.34 DDD/day X 10(3) inh) of L-dopa-containing drugs in the county of Gävleborg, warranted further analyses of subareas in this particular county. The use is discussed in relation to environmental factors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3825495     DOI: 10.1111/j.1600-0404.1986.tb03529.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  5 in total

Review 1.  How far are we in understanding the cause of Parkinson's disease?

Authors:  Y Ben-Shlomo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

2.  Effects of manganese oxide on monkeys as revealed by a combined neurochemical, histological and neurophysiological evaluation.

Authors:  H Eriksson; K Mägiste; L O Plantin; F Fonnum; K G Hedström; E Theodorsson-Norheim; K Kristensson; E Stålberg; E Heilbronn
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

3.  Whole-body lifetime occupational lead exposure and risk of Parkinson's disease.

Authors:  Steven Coon; Azadeh Stark; Edward Peterson; Aime Gloi; Gene Kortsha; Joel Pounds; David Chettle; Jay Gorell
Journal:  Environ Health Perspect       Date:  2006-12       Impact factor: 9.031

Review 4.  Epidemiology of Parkinson's disease.

Authors:  C M Tanner
Journal:  Neurol Clin       Date:  1992-05       Impact factor: 3.806

Review 5.  Epidemiology of Parkinson's disease.

Authors:  C M Tanner; S M Goldman
Journal:  Neurol Clin       Date:  1996-05       Impact factor: 3.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.